Filing Flows

Filing Flows › Companies › Biolife Solutions › Cash flow

Biolife Solutions cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$5.3M in Q2 2026 · $8.1M over twelve months

Operating cash flow$6.3M
Capital spending−$1.0M
Free cash flow+$5.3M
Cash / net income0.1×
Cash conversion cycle316 days

Analysis

In Q2 2026, Biolife Solutions generated $6.3M of operating cash flow and spent $1.0M on capital projects, leaving free cash flow of $5.3M. That is $320K less than in Q2 2025 ($5.6M).

Over the twelve months to Jun 30, 2026, operating cash flow was $16.9M; the largest uses were net borrowing (+) / repaid (−) ($10.0M), capital spending ($8.8M), other financing ($6.7M); besides operations, cash came from other investing ($531K), shares issued ($193K); the cash balance fell by $7.9M.

Operating cash flow was $6.3M against net income of $45.1M — 0.1× profit, less cash than reported earnings, worth checking against working capital. The largest differences: deferred taxes −$42.4M, stock-based pay +$3.9M, inventory −$2.8M.

Its cash conversion cycle was 316 days (receivables 38 + inventory 306 − payables 28).

Free cash flow

Biolife Solutions: free cash flow by quarterBiolife Solutions: free cash flow by quarter$4.8MQ3 2024$1.6MQ4 2024$1.6MQ1 2025$5.6MQ2 2025$6.1MQ3 2025$4.9MQ4 2025−$658KQ1 2026$5.3MQ2 2026
Operating cash flow less capital spending.
Biolife Solutions: operating cash flow against capital spendingBiolife Solutions: operating cash flow against capital spendingOperating cash flowCapital spending$4.8M$0Q3 2024$1.6M$0Q4 2024$1.7M$175KQ1 2025$7.4M$1.7MQ2 2025$6.1M$0Q3 2025$4.9M$0Q4 2025−$491K$167KQ1 2026$6.3M$1.0MQ2 2026
Latest (Q2 2026): Operating cash flow $6.3M, Capital spending $1.0M.

Capital allocation, year by year

Biolife Solutions: where the cash came from (up) and went (down), by fiscal yearBiolife Solutions: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$4.6MFY2021: Net borrowing −$4.2MFY2021: Shares issued $1.4MFY2021: Capital spending −$8.4M$1.4MFY2021FY2022: Operating cash flow −$8.5MFY2022: Net borrowing $18.3MFY2022: Shares issued $323KFY2022: Capital spending −$10.4M$18.7MFY2022FY2023: Operating cash flow −$12.5MFY2023: Net borrowing −$300KFY2023: Shares issued $10.8MFY2023: Capital spending −$6.4M$10.8MFY2023FY2024: Operating cash flow $8.4MFY2024: Net borrowing −$5.0MFY2024: Shares issued $202KFY2024: Asset sales $73.4MFY2024: Capital spending −$3.2M$82.1MFY2024FY2025: Operating cash flow $20.1MFY2025: Net borrowing −$10.0MFY2025: Shares issued $18KFY2025: Asset sales $23.5MFY2025: Capital spending −$9.5M$43.6MFY2025
Over these 5 years operating cash flow totalled $3.0M; the largest uses were capital spending ($37.9M) and operating cash flow ($25.6M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$82.4M
Debtnone
Net cash$82.4M
Due within a year$10.9M

Biolife Solutions funds itself: free cash flow was $8.1M over the last twelve months, with $82.4M of cash and investments and no debt on the balance sheet ($10.9M due within a year, 7.5× covered by cash).

Biolife Solutions: debt maturities by year (FY2024)Biolife Solutions: debt maturities by year (FY2024)$10.9MYear 1$5.0MYear 2
Principal due in each year as disclosed in the annual report, against $82.4M of cash and investments now.

Where the cash came from and went

Biolife Solutions: sources (+) and uses (−) of cash, Q2 2026Biolife Solutions: sources (+) and uses (−) of cash, Q2 2026Operating cash flow$6.3MNet borrowing (+) / repaid (−)−$2.5MCash drawn (+) / kept (−)−$1.2MTaxes on employees’ shares−$1.1MCapital spending−$1.0MOther investing−$536KShares issued$3K
Biolife Solutions: sources (+) and uses (−) of cash, TTM to Q2 2026Biolife Solutions: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow$16.9MNet borrowing (+) / repaid (−)−$10.0MCapital spending−$8.8MCash drawn (+) / kept (−)$7.9MOther financing−$6.7MOther investing$531KShares issued$193K

From profit to cash

Biolife Solutions: net income to operating cash flow, Q2 2026Biolife Solutions: net income to operating cash flow, Q2 2026Net income$45.1MDepreciation & amortization$411KStock-based pay$3.9MDeferred taxes−$42.4MReceivables$2.4MInventory−$2.8MPayables−$1.4MAccrued liabilities−$755KIncome taxes payable−$39KOperating cash flow$6.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20263830628316
Q1 20263428324294
Q2 20253730636308
Q1 20253635141346

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026$6.3M−$1.0M−$2.5M$3K−$1.2M$5.3M
Q1 2026−$491K−$167K−$2.5M$190K$10.2M−$658K
Q4 2025$4.9M—−$2.5M—−$3.6M$4.9M
Q3 2025$6.1M—−$2.5M—$2.4M$6.1M
Q2 2025$7.4M−$1.7M−$2.5M$18K$35.0M$5.6M
Q1 2025$1.7M−$175K−$2.5M—$28.4M$1.6M
Q4 2024$1.6M—−$2.5M$65K−$71.2M$1.6M
Q3 2024$4.8M—−$2.5M$46K−$2.1M$4.8M

Biolife Solutions: income statement and cash flow

Biolife Solutions, Q2 2026: revenue $28.5M (+22% year over year), operating margin 6.0%. The chart follows the revenue to costs, profit and cash.

Biolife Solutions: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.